Blockchain Registration Transaction Record

Theriva™ Biologics Hits Several Milestones in 2023, Positioning Itself for Growth as the Firm Targets Difficult-to-Treat Cancers

Theriva™ Biologics achieves significant milestones in 2023, positioning the company for growth in the development of therapies for difficult-to-treat cancers. The progress in clinical trials of VCN-01 and expansion of collaborations offer hope for improved treatment options, signaling promising advancements in cancer treatment.

The achievements of Theriva™ Biologics in 2023, particularly with the advancement of VCN-01 and the expansion of collaborations, signal promising progress in the development of therapies for difficult-to-treat cancers. The positive safety recommendations and enrollment progress in clinical trials of VCN-01 offer hope for improved treatment options for patients with pancreatic, retinoblastoma, head and neck, brain, and ovarian cancers. The company's efforts to address unmet needs for difficult-to-treat cancers have the potential to significantly impact the future of cancer treatment.